PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jclinpathJournal of Clinical PathologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Clin Pathol. 2006 October; 59(10): 1087–1090.
PMCID: PMC1861753

Pancreatic polypeptide cell hyperplasia of the pancreas

Abstract

A case of pancreatic polypeptide cell hyperplasia in a 76‐year‐old man who presented with subacute bowel pseudo‐obstruction is reported. A computed tomography scan incidentally showed a pancreatic head lesion that was resected by pancreaticoduodenectomy. Histological examination showed expansion of the endocrine pancreas with increased numbers of pancreatic polypeptide cells in irregularly enlarged islets, ragged endocrine cell clusters, ductulo‐insular complexes and microadenomas. The clinicopathological features of this rare and poorly understood condition are discussed.

Pancreatic polypeptide is produced by pancreatic polypeptide cells, which represent about 10% of the islets of Langerhans.1 It is released after ingestion of food and has inhibitory postprandial effects on gastric emptying, intestinal motility, exocrine pancreatic secretion, hepatic glucose production and gallbladder contraction.2 It is also associated with body weight regulation by influencing food intake and energy metabolism.3

Little is known about pancreatic polypeptide and disease. Published reports of pancreatic polypeptide cell hyperplasia (PPCH) will be reviewed and compared with the present case.

Case report

A 76‐year‐old man presented with epigastric pain, constipation and signs of subacute bowel obstruction. His medical history was unremarkable; in particular there was no personal or family history suggestive of multiple endocrine neoplasia type 1 (MEN I) syndrome. Although abdominal imaging failed to show any cause of obstruction, a computed tomography scan showed a heterogeneous lesion in the pancreatic head, a dilated biliary tree and pancreatic duct, and an atrophic pancreas. Whipple's resection was uneventful. Slicing of the pancreatic head (4×2.5×1.5 cm) showed firm, lobulated parenchyma without evidence of a circumscribed lesion. The common bile duct was slightly dilated. The duodenum and ampulla were normal.

Histological examination showed diffuse islet cell hyperplasia and ductulo‐insular complex (DIC) formation (ie, endocrine cells budding from duct epithelium). The islets were increased in number and size, with irregular outlines, replacing parts of the otherwise normal acinar lobules. They showed an abnormal trabecular and pseudoglandular architecture (fig 11).). Synaptophysin immunostaining confirmed these findings (fig 22).). Whereas most islets, irregular endocrine cell clusters and DICs harboured α, β, δ and pancreatic polypeptide cells, the quantitative and spatial relationship of these cell populations was disrupted in some of the enlarged islets and cell clusters (so‐called islet cell dysplasia). Immunostaining for pancreatic polypeptide showed that between 10% and >50% of all endocrine cells, both in the enlarged islets and DICs, produced pancreatic polypeptide ((figsfigs 3, 44),), a finding that is markedly higher than even that in the pancreatic polypeptide cell‐rich ventral portion of the normal pancreas (<10%). The normal spatial distribution of islet cells was lost as pancreatic polypeptide cells occupied both a central and a peripheral position in the enlarged islets (fig 55).). Mitotic figures were not identified, and Ki‐67 immunostaining showed few positive nuclei (<1%) in the endocrine compartment.

figure cp30478.f1
Figure 1 Expansion of the endocrine compartment is characterised by irregular and coalescent endocrine cell clusters with trabecular growth pattern. Arrows indicate residual pancreatic acini (haematoxylin and eosin ×50).
figure cp30478.f2
Figure 2 Immunostaining for synaptophysin confirms the expansion of the endocrine compartment (×50).
figure cp30478.f3
Figure 3 Immunostaining for pancreatic polypeptide (PP) shows that a large proportion of the expanded endocrine cell population expresses PP (×50).
figure cp30478.f4
Figure 4 Ductulo‐insular complex, that is endocrine cell clusters budding from small ducts (arrows), are present (immunostaining for synaptophysin ×200).
figure cp30478.f5
Figure 5 Immunostaining shows loss of the normal spatial and quantitative relationship of islet cells producing insulin (A), glucagon (B), somatostatin (C) and pancreatic polypeptide (D); (×100).

A few of the endocrine cell clusters were distinct from the others by their larger size (<0.8 mm), smooth contour, sharp delineation from adjoining parenchyma and monohormonal secretion of pancreatic polypeptide (fig 66),), findings that meet the diagnostic criteria of endocrine microadenomas. The endocrine cell population comprised in a focus of ectopic pancreatic tissue in the ampulla and surrounding duodenal wall, showed changes similar to those in the pancreatic head.

figure cp30478.f6
Figure 6 A relatively large (0.7 mm) compact and well‐delineated endocrine cell cluster, which showed monohormonal pancreatic polypeptide expression on immunostaining (haematoxylin and eosin ×50).

These findings were reported as PPCH, with the possible presence of pancreatic polypeptide cell microadenomas. Unfortunately, preoperative serum levels of pancreatic polypeptide were not measured.

Discussion

Proliferative changes associated with pancreatic polypeptide cells include three conditions:

  • tumours exclusively or predominantly composed of pancreatic polypeptide cells (“PPomas”),
  • pancreatic endocrine tumours (PETs) in which pancreatic polypeptide cells are part of a mixed tumour cell population (mixed PETs) and
  • PPCH.

The condition described as PPCH is surrounded by confusion due to inconsistencies in histological criteria and terminology. This may be related to the heterogeneous distribution of pancreatic polypeptide cells throughout the pancreas and the ensuing sampling problems. Pancreatic polypeptide cells are mostly confined to the pancreatic region of ventral embryological origin,1 whereas islets of the tail, body and other parts of the pancreatic head contain only a small number of these cells. Within the islets, pancreatic polypeptide cells often take up a peripheral position, mixed with α and δ cells.

In this case, pancreatic histology was characterised by marked expansion of the endocrine compartment in the form of irregularly enlarged islets or ragged cell clusters and foci of DICs. The normal spatial and quantitative relationship between the four islet cell populations was disrupted (so‐called islet cell dysplasia) and characterised by a marked increase in pancreatic polypeptide cells. Interestingly, similar pancreatic polypeptide cell changes were present in a small focus of ectopic pancreatic tissue in the periampullary duodenal wall, suggesting that the process may be diffuse, affecting the entire pancreas.

The clinical presentation of pancreatic polypeptide hypersecretion is usually silent. In this case it could be speculated that intestinal (pseudo‐) obstruction was effected by the inhibitory action of pancreatic polypeptide on the upper gastrointestinal tract. Of the seven published cases of PPCH (table 11),4,5,6,7 three were associated with and assumed to be the cause of watery diarrhoea syndrome (Verner–Morrison syndrome).4,5,6 This assumption was not supported by other observations, as highly increased pancreatic polypeptide levels were found in the plasma without concomitant diarrhoea or achlorhydria. PPCH has also been reported in three patients with sporadic pancreatic or duodenal gastrinoma.7 In one of these patients, PPCH was seen 15 years after normalisation of gastrin levels by removal of a pancreatic gastrinoma, a finding arguing against a trophic role for hypergastrinaemia in the development of PPCH. Initial studies reported diffuse pancreatic polypeptide cell changes in the context of MEN I syndrome; however, subsequent large MEN I series identified microadenomatosis (ie, multiple well‐circumscribed monohormonal tumours) as the most distinctive feature, while PPCH did not belong to the spectrum of lesions.8 Hence, the association of PPCH seems to be limited to sporadic gastrinoma (and possibly other sporadic PETs), whereby the relationship between the two lesions remains unclear.

Table thumbnail
Table 1 Clinicopathological details of case reports of PPCH in the literature

The morphological changes associated with the pancreatic polypeptide cell population in our case are remarkably similar to those of β cells in persistent hyperinsulinaemic hypoglycaemia, a rare condition in neonates and also in adults.9 Interestingly, similar histological changes affecting the α cells have recently been described,10 indicating that functional and morphological abnormalities may affect all three cell types. With the genetic defects underlying persistent hyperinsulinaemic hypoglycaemia being identified,11 abnormalities of genes controlling pancreatic polypeptide release could in a parallel way lead to similar histological changes. Although diffuse hyperplasia characterises the adaptive process of the affected β, α or pancreatic polypeptide cell population, the presence of a few microadenomas in this case suggests that neoplastic transformation may occur if the underlying cause is longstanding and unabated. As the prognosis of PPCH is unknown, long‐term follow‐up is recommended.

Abbreviations

DIC - ductulo‐insular complex

MEN I - multiple endocrine neoplasia type 1

PET - pancreatic endocrine tumour

PPCH - pancreatic polypeptide cell hyperplasia

Footnotes

Competing interests: None.

References

1. Bommer G, Friedl U, Heitz P U. et al Pancreatic PP cell distribution and hyperplasia: immunocytochemical morphology in the normal human pancreas, in chronic pancreatitis and pancreatic carcinoma. Virchows Arch A 1980. 387319–331.331.
2. Miller L J. Gastrointestinal hormones and receptors. In: Yamada T, Alpens DH, Laine L, Owyang G, Powel DW, eds. Textbook of gastroenterology. New York: Lippincott, 1999. 35–66.66.
3. Asakawa A, Inui A, Yuzuriha H. et al Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003. 1241325–1336.1336. [PubMed]
4. Tomita T, Kimmel J R, Friesen S R. et al Pancreatic polypeptide cell hyperplasia with and without watery diarrhea syndrome. J Surg Oncol 1980. 1411–20.20. [PubMed]
5. Farley D R, van Heerden J A, Myers J L. Adult pancreatic nesidioblastosis. Unusual presentations of a rare entity. Arch Surg 1994. 129329–332.332. [PubMed]
6. Pasieka J, Hershfield N. Pancreatic polypeptide hyperplasia causing watery diarrhea syndrome—a case report. Can J Surg 1999. 4255–59.59. [PubMed]
7. Martella E M, Ferraro G, Azzoni C. et al Pancreatic‐polypeptide cell hyperplasia associated with pancreatic or duodenal gastrinomas. Hum Pathol 1997. 28149–153.153. [PubMed]
8. Klöppel G, Willemer S, Stamm B. et al Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. Cancer 1986. 571824–1832.1832. [PubMed]
9. Klöppel G, Reinecke‐Lüthge A, Koschorek F. Focal and diffuse beta cell changes in persistent hyperinsulinemic hypoglycemia of infancy. Endocr Pathol 1999. 10299–304.304. [PubMed]
10. Martignoni M E, Kated H, Stiegler M. et al Nesidioblastosis with glucagon‐reactive islet cell hyperplasia—a case report. Pancreas 2003. 26402–407.407. [PubMed]
11. Meissner T, Beinbrech B, Mayatepek E. Congenital hyperinsulinism: molecular basis of a heterogeneous disease. Hum Mutat 1999. 13351–361.361. [PubMed]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Group